12% of the United states population, including 18% of women, 6% of men and 4% of children. Lifetime prevalence of migraine in women in the United States exceeds 25%. The prevalence of migraine has not changed since 1989, which was based on evidence from three large studies: American Migraine study-I, American Migraine Study-II and American Migraine Prevention and prevalence study. The basic principle in management of migraine is avoiding the trigger factors, blocking the mediators 4 . Sodium valproate and pizotifen can be used in the prophylaxis of migraine and the potential effectiveness of sodium valproate in migraine prophylaxis is well established.
Materials and Methods:
This study was a single blind randomized clinical trial carried out in the department of neurology at BSMMU, Dhaka from January 2010 to December 2011 for a duration of two years among patients of both sexes between 16-50 years who presented with migraine and were enrolled in this study. Migraine patient were selected according to INTERNATIONAL HEADACHE SOCIETY (IHS) criteria who were not on prophylactic medication & patients having hepatic or renal impairment, pregnancy and prostatism were excluded from the study.
Observation and Results:
A total of 120 patients were included as study population and were divided into two groups, group-A (60 patients) and group-B(60 patients). The group-A took sodium valproate (400-1200 mg/day) and the group-B took pizotifen (0.5-3.00 mg/day) for total 6 months duration. 
Discussion:
In this present study a total of 120 patients were studied and divided into two groups, group-A and group B. The group-A took the sodium valproate and group-B took the pizotifen given with definite doses & duration. In group-A majority were in the age group of 20-29 years which was 23 (38.3%) followed by 30-39 years which was16(26.7%) and less than 20 years which was 14 (23.3%). Only 7 (11.7%) cases were in the age group of 40 years and above. In group-B majority were in the age group of 20 -29 years which was 22 (36.7%) followed by age group of 30 -39 years which was 17 (28.3%) and less 20 years which was 15 (25.0%) cases. Only 6 (10.0%) cases were in the age group of 40 years and above. It was reported in a study that migraine usually develops in childhood, adolescence or adulthood 11 . In a study 12 it was also reported that headache intensity declined from 40 years to 74 years with change in headache frequency or duration which is consistent with this study and also consistent with the previous study done in Bangladeshi population 13 .
In both groups female was predominant which was 49(81.7%) cases in group A and 49 (81.7%) cases in group B. Pietrobon D and Striessnig J. reported that female was more vulnerable than male in respect to migraine which is consistent with this present study 11 . Russell et. al. 14 found that there was a significant preponderance of females of all the subtypes of migraine which is also consistent with the present study and also consistent with the previous study done in Bangladeshi populations 13 . .3% respectively (p = 0.006). The difference was statistically significant (p=0.009). After 2 months of treatment duration of episode was recorded in group A minutes, minutes to hours and hours to days 44.1%, 55.9% and 0.0% cases and in group B minutes, minutes to hours and hours to days 30.0%, 66.7% and 3.3% cases respectively (p=0.128). After 4 months of treatment duration of episode was recorded in group A minutes, minutes to hours and hours to days 90.0%, 10.0% and 0.0% cases and in group B minutes, minutes to hours and hours to days 60.4%, 37.5% and 2.1% cases respectively (p=0.007). After 6 months of treatment duration of episode was recorded in group A minutes, minutes to hours and hours to days 88.0%, 12.0% and 0.0% cases and in group B minutes, minutes to hours and hours to days 51.3%, 46.2% and 2.6% cases respectively (p=0.010). The difference was statically significant (p=0.01).
Frequency of attack per month after 2 months treatment was 4.69 ± 3.46 and 6.56 ± 5.14 in group A and group B respectively (p=0.022). Frequency of attack per month after 4 months of treatment was 2.51 ± 2.20 and 3.88 ± 2.83 in group A and group B respectively (p=0.004). Frequency of attack per month after 6 months of treatment was 1.60 ± 1.87 and 2.76± 1.98 in group A and group B respectively (p=0.023). The difference is statistically significant (p=0.023) which is consistent with the previous study done in Bangladeshi populations 13 . So, sodium valproate is more beneficial than Pizotifen in the prophylaxis of migraine.
Conclusion:
The finding of this study permit to conclude that the efficacy of sodium valproate is more than Pizotifen in the prophylactic management of migraine patient.
